Tremendous progress has been made in the war on cancer, leading to improvements in cancer prevention, detection, and treatment. Together, these advances have resulted in decreasing incidences and a steadily declining death rate from cancer. However, for patients who develop stage IV cancer, cancer that has spread to distant organs, their prognosis remains grim. Conventional chemotherapy is limited in its ability to successfully eradicate metastatic disease. Therefore, new modalities and approaches are desperately needed if we are to make progress toward conquering this last mountaintop of cancer research. This book lays out the rationale for a novel therapeutic strategy using new targeted drugs to develop effective ways to treat patients with metastatic cancer. This strategy uses artificial intelligence methods to leverage the vast amounts of genomic data that have become available in recent years to develop precise and personalized methods of treating patients with metastatic cancer. This strategy, together with modern approaches to immunotherapy, offers hope to the eventual routine cure of metastatic cancer.
Auflage
Sprache
Verlagsort
Newcastle upon Tyne
Großbritannien
Zielgruppe
Editions-Typ
Produkt-Hinweis
Maße
Höhe: 212 mm
Breite: 148 mm
ISBN-13
978-1-5275-9230-8 (9781527592308)
Copyright in bibliographic data and cover images is held by Nielsen Book Services Limited or by the publishers or by their respective licensors: all rights reserved.
Schweitzer Klassifikation
Stephen P. Ethier, PhD, is Professor of Pathology and Laboratory Medicine at the Medical University of South Carolina, having previously served as Associate Director for Basic Research and Deputy Director of the Barbara Ann Karmanos Cancer Institute, and Professor of Oncology at Wayne State University, USA. Dr Ethier has spent his entire career studying the biology of breast cancer. In recent years, his work has focused on the genomic alterations that drive breast cancer development and how those genomic changes lead to the expression of malignant phenotypes and drug sensitivities in breast cancer cells. His publications include over 140 peer reviewed scientific papers, and The Lewis Exchange, his first work of fiction.
